A few key buyouts have helped transform Shire Therapeutics over the past decade from a "one-trick pony" to a diversified pharma group with a string of marketed products and leadership roles in several strategic areas. It hasn't hurt that Shire was an early convert to orphan drugs, one of the hottest fields in pharma R&D these days. And Shire CEO Angus Russell is getting the lion's share of the credit, as this profile from The Wall Street Journal underscores. Story